UNSPSC 51313202: Bamipine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y6BHZ28O92, chemically known as 4-piperidinamine, 1-methyl-n-phenyl-n-(phenylmethyl)- but generally known as bamipine, which bears US NIH Compound Identifier 72075. Bamipine most often comes in base, dihydrochloride, and hydrochloride forms. European Medicines Agency schedules Bamipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06098MIG.

UNSPSC 51313202 Bamipine is a Commodity code that encompasses pharmaceutical products, though recent state and local activity under this code focuses on procurement of naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products rather than bamipine specifically. State and local governments soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances representing multiple jurisdictions. The work being procured ranges from emergency response medications (naloxone for opioid overdose reversal) to comprehensive generic pharmaceutical supply agreements serving health plans, employee benefit programs, and public health facilities. Issuing bodies require vendors to meet federal compliance standards including FDA requirements, cGMP certification, Drug Supply Chain Security Act adherence, E-Verify employment verification, and often carry proof of commercial general liability, workers' compensation, and professional liability insurance.

Activity under this code appears primarily in Florida and Texas, with multi-state involvement through cooperative purchasing vehicles. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building and a response deadline of July 26, 2023 (note: the deadline date appears inconsistent with the posting date in the source). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, positioning it as exploratory research before formal RFP issuance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract awards effective July 1, 2026. No explicit small-business set-asides or disadvantaged-enterprise restrictions were noted across these solicitations.